Sagentia Moves United States Headquarters to Larger Location in Boston, Mass.

The move to One Beacon Street will provide Sagentia the space necessary to thrive

Sagentia Moves United States Headquarters to Larger Location in Boston, Mass.

<0> SagentiaTamara Kahn, +44 1223 875205Vice President, Corporate DevelopmentorRacepoint GroupNicole Franklin, 617-624-3223Account Director </0>

Sagentia, a global innovation, technology and product development company, today announced that their United States headquarters has moved from the Cambridge Innovation Center in Cambridge, Mass. to One Beacon Street in Boston. Sagentia develops new technologies and breakthrough products that help change the basis of competition for its clients, from startups to global leaders in three global sectors: medical, consumer products and industrial. The new office, over 3 times larger than their previous space, will give Sagentia the room needed to continue to grow their presence in the U.S.

“The relocation to Boston places Sagentia in close proximity to a wealth of world-renowned university research hospitals, which will provide a rich environment to help the company grow,” said Peter Thier, senior vice president of business development at Sagentia. “Massachusetts has a thriving life sciences industry, and Sagentia is thrilled to continue to play a vital role in that community.”

The move comes on the heels of particularly strong customer growth in North America, providing Sagentia the opportunity to continue to be a strong leader in product innovation, science and technology consulting and product development. Particularly in today’s economy, Sagentia’s ability to bridge market needs with viable concept generation, proof of principle demonstrators and prototyping is an invaluable service to its customers.

“We are pleased that Sagentia is continuing to grow their presence in Massachusetts,” said Ann Merrifield, chief executive officer of PathoGenetix, developer of an automated system for rapid identification of bacterial strains. “As PathoGenetix prepares to launch its Genome Sequence Scanning technology, we are fortunate to have a critical partner in its commercialization located in our own backyard. Having a team that understands our core objectives so easily accessible is a huge asset.”

“Sagentia’s ability to combine theoretical modeling, product design and prototyping are key as an R&D partner,” said Stephen Trotta, Vice President of R&D Instrument Development at Instrumentation Laboratory. “We are happy to hear about their growth in the US with this move to Boston and look forward to hearing about their continued success.”

Sagentia responds to its clients' needs in three important ways: helping companies meet the challenges of product innovation as the core driver for competitive advantage in both developed and developing markets, partnering with companies on co-development and open innovation and helping companies to adapt to global market changes with an increasing focus on usability, product efficacy, personalization and cost reduction.

This announcement follows a recent change in Sagentia’s leadership, with Dan Edwards and Mick Withers appointed as co-Managing Directors of the business. The change takes place as Sagentia continues to build on its strong science, technology and engineering base with focused market insight to meet the growing needs of its clients.

Sagentia is a global innovation, technology and product development company. We provide outsourced R&D consultancy services to start ups through to global market leaders in the medical, industrial and consumer sectors. With global headquarters in Cambridge, UK, and US headquarters in Boston, Massachusetts, Sagentia works with clients from opportunity discovery through to concept generation and full product development and transfer to manufacture. We deliver science and technology innovation and work with clients to develop next generation products and services that provide commercial value and market advantage. Further information can be found at: . Email us

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.